Fuad El-Hibri Wire

Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock:

On January 20, 2009, Emergent Biosolutions announces that Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock: 13.5 million shares had been issued to date with 47% controlled by Fuad El-Hibri. It also announced Stage II testing of vaccines for Typhoid, Hepatitis B, and Tuberculosis.

El-Hibri Fuad, Fuad El-Hibri, Fuad Elhibri, Tuberculosis Vaccine

Tuberculosis Vaccine by Fuad El-Hibri

Fuad El-Hibri’s EBS is Developing TB Vaccine

Jun 15
Comments

Fuad El-Hibri’s EBS is Developing TB Vaccine

“The search for a new TB vaccine is a complex and challenging process requiring a broad commitment, and we are pleased to be collaborating with so many dedicated and talented researchers on this important effort,” said Jerald C. Sadoff, president and CEO of Aeras, in a statement.

“This marks an important milestone in what we believe is an extraordinary opportunity to prevent tuberculosis, which is a major global health crisis. Emergent is proud to join such distinguished partners as we make progress in the fight against one of the world’s deadliest diseases,” said Fuad El-Hibri, chairman and CEO of Rockville biotech Emergent BioSolutions, which is teaming with the University of Oxford on the TB project.

---

Posted in El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri, TB Vaccine, Tuberculosis Vaccine
Tags: Aeras Global TB Vaccine Foundation, Chief executive officer, Conditions and Diseases, Global health, Health, Infectious Diseases, Oxford University, Tuberculosis

Fuad El-Hibri Key Executive at Emergent